enzyme immunoassay with synthetic peptides to detect anti-htlv-i antibodies.

NLM AIDSLINE Enzyme immunoassay with synthetic peptides to detect anti-HTLV-I antibodies. Yamada K; Kuroda N; Washitani Y; Shiraki H; Maeda Y; Central Research
August 30, 1992

Clin Chem. 1992 May;38(5):699-703. Unique Identifier : AIDSLINE We developed an enzyme immunoassay (EIA) system to detect antibodies to human T-lymphotropic virus type I (HTLV-I). This system uses chemically synthesized oligopeptides to capture anti-HTLV-I antibodies in serum. The two epitopes of HTLV-I proteins exhibiting the most specific antigen-antibody reaction reside within amino acids 100-130 of p19, a core protein encoded by gag, and amino acids 175-199 of gp46, an envelope glycoprotein encoded by env. This new assay uses synthetic peptides corresponding to these two regions modified by adding two lysine residues at the amino terminal of each peptide to facilitate the binding to the surface of the microtiter plate wells. We compared the performance of our EIA with gelatin-particle-agglutination (PA) and indirect-immunofluorescence (IF) assays, both of which use viral proteins purified from virus-carrying cell cultures. Mass screening by EIA with various synthetic peptides was more accurate than the current confirmatory IF assay. Agglutination Tests Comparative Study Fluorescent Antibody Technique Gene Products, env/IMMUNOLOGY Gene Products, gag/IMMUNOLOGY Human HTLV-I Antibodies/BLOOD HTLV-I Antigens/IMMUNOLOGY Immunoenzyme Techniques JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 NEW YORK: Catskill Hospital Warns That Insulin Pens May Have Been Reused DELAWARE: Cape Henlopen Theatre Academy to Host 'Magic to Do' May 25 GLOBAL: HIV Outcomes Could Improve by Integrating Treatment of Comorbid Mental Illness CANADA: Stop Paid Blood Donor Clinics in Toronto, Victims Say UNITED STATES: How Sexual Stigma Is Undermining HIV Treatment on American Indian Reservations HHS Office for Civil Rights launches campaign to increase awareness of HIPAA rights among HIV-positive Black men Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog La lutte anti-sida de demain: pas de baguette magique mais un cocktail Russia has 'no anti-AIDS strategy': official PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents NIH Scientists Create New Tool for Identifying Powerful HIV Antibodies: Advance Could Speed HIV Vaccine Research Feuding antibodies blocked HIV vaccine Challenge to overcome earlier anti-gay prejudices Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies Free Speech and an Anti-Prostitution Pledge Anti-HIV therapy appears to protect children's hearts, NIH network study shows Antibody evolution could guide HIV vaccine development
Information in this article was accurate in August 30, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.